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Background. There is growing interest to use ascorbic acid
as adjuvant therapy for patients with recombinant human
erythropoietin-hyporesponsiveness (rHuEpo). Several clinical
studies showed the beneficial effect of ascorbic acid treatment
on hematologic parameters in rHuEpo-treated hemodialysis
patients with elevated or even normal iron stores. However,
whether ascorbic acid directly affects stability and cellular
metabolism of intravenous iron preparations (IVI) is not well
understood.
Methods. The preparations for testing were iron sucrose
(Venofer), ferric gluconate (Ferrlecit), and iron dextran
(INFeD). HepG2-cells were used to investigate effects of ascor-
bic acid on iron bioavailability for the intracellular labile iron
pool (LIP) from IVI by using the fluorescent calcein-assay, and
cellular ferritin content was measured by enzyme-linked im-
munosorbent assay (ELISA). Transferrin-chelatable iron was
assessed by fluorescent-apotransferrin, and cell toxicity was as-
sayed by neutral red cytotoxicity test.
Results. The effects of vitamin C on different preparations
do not reflect their known chemical stability (i.e., iron dextran
>iron sucrose >ferric gluconate). Effects of ascorbic acid on the
increase of the intracellular LIP, as well as on increasing mobi-
lization to transferrin in serum, were limited to iron sucrose.
Ascorbic acid did not increase cell toxicity and the amount of
low molecular weight iron in serum.
Conclusion. We conclude that corrected ascorbic acid levels
in hemodialysis (HD) patients could increase the amount of
bioavailable iron from iron sucrose, but not from other classes
of IVI. Vitamin C administration could therefore result in a
lower need of iron sucrose to correct anemia.
Intestinal iron absorption is insufficient to meet the
enhanced iron demand in recombinant human erythro-
poietin (rHuEPO) treated hemodialysis (HD)-patients
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[1]. Most of them require intravenous iron to sustain ad-
equate erythropoiesis. Parenteral iron preparations are
therefore widely used for the treatment of iron deficiency
anemia in patients under chronic hemodialysis [2–5].
Several parenteral iron formulations exist for adminis-
tration to patients with end-stage renal disease (ESRD)
[6]. The preparations are complexes of ferric iron with
polymeric carbohydrates like dextran or sugars like su-
crose or gluconate-forming polynuclear complexes with
the metal [7]. Recently, also ferric pyrophosphate (Fe-PP)
has been used as a direct dialysis supplement [8]. These
iron complexes are largely degraded in reticuloendothe-
lial cells, from where the iron is delivered to transferrin
and further to the erythroblastic cells of the bone mar-
row. The half-life of intravenous iron is several hours,
depending on the molecular properties of the individual
preparations [7, 9]. Thus, other tissues of the body are
confronted with this form of iron at concentrations in the
range between 10 and 500 lmol/L, depending on the dose
used and the rate of infusion.
Iron therapy is important in anemic ESRD patients
to achieve an adequate iron status defined as transferrin
saturation (TS) higher than 20%, serum ferritin higher
than 100 lg/L, and serum iron greater than 80 lg/dL [10].
Some HD patients with increased iron deposits exhibit
rHuEPO hyporesponsiveness due to an inadequate iron
mobilization and defective iron utilization [11].
Functional iron deficiency is characterized by both low
TS and serum iron despite normal or elevated iron stores.
TS shows circadian variations caused by wide fluctuations
in reticuloendothelial iron release [12]. Nevertheless, TS
remains a reliable parameter of iron availability. In recent
studies, it has been demonstrated that TS <20% corre-
lates with new markers of functionally iron-deficient ery-
thropoiesis [13–15].
The potential role of adjuvant therapies in enhancing
the effectiveness of rHuEPO in ESRD patients has re-
ceived increasing attention in recent years. The important
reason to search for adjuvant therapies is that they may
help to overcome rHuEPO-hyporesponsiveness.
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Plasma concentrations of ascorbic acid are often de-
creased in patients with iron overload. This may be due
to increased vitamin oxidation catalyzed by iron. More-
over, subclinical ascorbic acid deficiency is frequently en-
countered in HD patients, owing to insufficient dietary
intake, loss through the dialyzer, and uremia-associated
metabolic derangement [16]. Unsupplemented dialysis
patients reportedly have lower plasma levels of ascor-
bate in comparison to healthy controls, mostly due to a
loss into the dialysate or, in case of nondialyzed patients,
increased urinary loss [17].
Ascorbate represents one of the most prominent an-
tioxidants both in plasma as well as intracellularly,
exerting beneficial effects by an inhibition of lipid per-
oxidation and by reducing endothelial dysfunction [17–
20]. In the presence of transition metals like iron, ascor-
bate may give rise to an increased generation of oxidants
[17, 21–23]. However, other recent studies in humans and
animals have provided no evidence in support of a pro-
oxidant activity of vitamin C in vivo [24–29].
In addition, ascorbic acid, as a reducing agent, is able
to release iron from ferritin and mobilize iron from the
reticuloendothelial system to transferrin, which leads to
increased iron availability and may prevent tissue iron
overload [30, 31].
Berger et al showed that addition of iron to ascorbic
acid-deficient plasma immediately resulted in the forma-
tion of lipid hydroperoxides, whereas endogenous and
exogenous ascorbic acid in the plasma delayed the onset
of iron-induced lipid peroxidation in a dose-dependent
manner. These findings indicate that in iron-overloaded
plasma, ascorbic acid acts as an antioxidant toward lipids
[32].
In this study, we investigated the effects of ascorbic acid
on the amount of chelatable and bioavailable iron from 3
different classes of IVI preparations in human hepatoma
HepG2 cells. These cells are a suitable model because
the liver is the main sink for iron. The preparations se-
lected are commonly used in the clinical treatment of HD
patients.
METHODS
Materials
Calcein and its acetoxymethylester (Calcein-AM)
were obtained from Molecular Probes (Eubio, Vienna,
Austria). The iron chelator salicylaldehyde isonicotinoyl
hydrazone (SIH) was a generous gift from Dr. Prem
Ponka (Lady Davis Institute for Medical Research, Mon-
treal, Canada), and was prepared as 5 mmol/L stock
solution in dimethyl sulfoxide (DMSO). Diethylene-
triaminepentaacetic acid (DTPA), ferric-pyrophosphate
(Fe-PP), ferrous ammonium sulfate (FAS), human
apo-transferrin (apo-transferrin; aTF), and HEPES
were from Sigma (Vienna, Austria), 5-(4,6-dichloro-
triazinyl)aminofluorescein (DCTAF) from Molecular
Probes, Inc. (Eugene, OR, USA).
Iron preparations
The preparations for testing were iron sucrose
(Venofer) from Vifor, St. Gallen, Switzerland, ferric
gluconate (Ferrlecit) from Rhone-Poulenc Rorer, A.
Nattermann & Cie, and iron dextran (INFeD) from
Schein Pharmaceuticals (Florham Park, NY, USA). The
preparations were dissolved in phosphate-buffered saline
(PBS: 137 mmol/L NaCl, 2.65 mmol/L KCl, 1.45 mmol/L
K2HPO4, 8.45 mmol/L Na2HPO4 × 12 H2O, pH 7.3) and
freshly prepared for each experiment.
Study design
To assess whether ascorbic acid supplementation has
effects on iron bioavailability we compared the increase
of the intracellular labile iron pool (LIP) by parenteral
iron in the presence and absence of ascorbic acid in a
tissue culture model with human hepatoma HepG2 cells.
The intracellular labile iron pool (LIP) was studied by the
fluorescent calcein-assay [33]. The expression of several
proteins important in iron metabolism is regulated by
the iron regulatory proteins (IRPs). The activity of IRPs
themselves depends on the size of the LIP. Changes in the
size influence expression of proteins (e.g., ferritin), which
are regulated by IRPs. An increase in the LIP should
therefore result in increased ferritin synthesis. Therefore,
we tested if ascorbic acid treatment influences ferritin
expression in HepG2 cells.
One important concern in treatment of patients with
ascorbic acid is the occurrence of possible pro-oxidant ef-
fects when iron is present. We therefore tested if ascorbic
acid treatment increases cytotoxicity of iron preparations
in HepG2 cells by using a neutral red (NR) cytotoxicity
assay, which can distinguish between viable, damaged, or
dead cells [34]. Alternations of the cell surface or the sen-
sitive lysosomal membrane, which can be caused by cy-
totoxic compounds, lead to lysosomal fragility and other
changes that gradually become irreversible. Such changes
result in a decreased uptake and binding of NR.
To assess whether vitamin C directly affects chemical
stability of the preparations, the amount of chelatable
iron from parenteral iron preparations was assayed with
3 different in vitro tests: assay for transferrin chelatable
iron, assay for ferrozine-chelatable ferrous iron, and as-
say for low-molecular-weight iron in serum.
In the assay for transferrin chelatable iron, fluorescent
apotransferrin (which is the iron-free form of transfer-
rin) was added to transferrin-depleted serum and used as
a sensitive fluorescent probe to detect iron chelation by
transferrin. When iron binds to fluorescent apotransfer-
rin its fluorescence is stoichiometrically quenched [35].
This in vitro test for transferrin-chelatable iron is of
physiologic importance because transferrin is also the
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physiologic iron transporter in the plasma and, therefore,
supplies the erythron with iron for hemoglobin synthesis.
With the assay for ferrozine-chelatable ferrous iron
(Fe2+), another important aspect of direct interaction of
ascorbic acid with iron preparations can be monitored;
ascorbic acid not only has iron chelating properties, but
is also a strong reductant. This test was used to measure
the amount of reductive iron release from the iron prepa-
rations [all of them are polynuclear complexes of ferric
iron (Fe3+)] by ascorbic acid. The biological significance
of such a reductive iron release seen in vitro is that ferrous
iron could then be taken up by various cells expressing
the divalent metal transporter DMT1 and, therefore, in-
crease cellular iron uptake from the preparations by these
cells. Ferrozine-chelatable iron chemically represents fer-
rous iron (Fe2+), which can, in principle, catalyze Fenton
reaction. Different amounts of ferrozine-chelatable iron
in the preparations alone and in the presence of ascorbic
acid could therefore cause differences in cytotoxicity.
Effects of ascorbic acid on the amount of low-
molecular-weight iron could result in the appearance of
potentially redox-active low-molecular-weight iron in the
plasma, leading to generation of oxidative stress. To as-
say if ascorbic acid increases low-molecular-weight labile
iron in serum, ultrafiltration experiments were performed
using an ultrafilter with a 10 kD molecular weight cut-off.
The amount of iron before and after ultrafiltration was
measured by atomic absorption spectroscopy.
Assessment of bioavailable iron
(fluorescent calcein-assay)
HepG2-cells were used to assay the effect of ascor-
bic acid on iron-bioavailability from parenteral iron
preparations by the fluorescent calcein-assay [33]. In
this assay the fluorescent metal binding dye calcein
is used to measure intracellular iron levels. Calcein-
acetoxymethylester permeates through cell membranes
due to its lipophilic acetoxymethylester. Once inside the
cell, the acetoxymethylester group is cleaved by nonspe-
cific esterases, resulting in free fluorescent calcein, whose
fluorescence is quenched by intracellular labile iron. To
estimate the amount of the intracellular LIP, calcein flu-
orescence is measured before and after addition of the
strong fast permeating iron chelator isonicotinoyl sali-
cylaldehyde hydrazone (SIH) to the cells to obtain full
fluorescence of calcein. The measured increase in calcein
fluorescence is proportional to the size of the intracellular
LIP.
The cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM)-medium containing 10% fetal calf
serum, 2 mmol/L L-glutamine, and antibiotics (gen-
tamycin 50 lg/mL). Cells were treated with trypsin
(1.25×), and resuspended in DMEM-medium and grown
on 48-well plates at a density of 1 × 106cells/mL.
After 2 days the cells were in the log-phase and were
used for the measurement of the LIP. To remove any
surface-bound iron, the cells were washed with DMEM-
medium containing 50 lmol/L DTPA and 2 more wash-
ings with DMEM-medium alone, and then loaded with
0.25 lmol/L calcein-AM for 15 minutes at 37◦C in
DMEM-medium, and buffered with 20 mmol/L HEPES.
The cells were washed of excess calcein-AM and re-
suspended in DMEM-medium containing 20 mmol/L
HEPES and a fluorescence-quenching anticalcein anti-
body (10 lL/mL medium) that was added to eliminate
extracellular fluorescence. The anticalcein antibody was
made by Dr. Marcela Hermann, Department of Medical
Biochemistry, University of Vienna, Austria (method by
Breuer et al, Hebrew University, Jerusalem, Israel) [36].
Calcein fluorescence is quenched by intracellular labile
iron. Calcein fluorescence was measured in a fluorescence
plate reader (Victor II) from Perkin Elmer (excitation
485 nm, emission 535 nm; Vienna, Austria) at 37◦C. Af-
ter stabilization of the signal, the amount of intracellular
iron that was bound to calcein (Ca-Fe) was assessed by ad-
dition of 100 lmol/L of the fast permeating chelator SIH
to remove all iron from calcein, and hence, to obtain max-
imal fluorescence. The increase in calcein fluorescence is
proportional to the size of the intracellular LIP.
Ferritin measurements
Cells were incubated with 75 lmol/L of IVI between 0
and 24 hours, washed, harvested, and lysed on ice in NP-
40 lysis buffer containing 150 mmol/L NaCl, 1% IGEPAL
CA-630 (NP-40), 50 mmol/L Tris, pH 8, and 1 mmol/L
PMSF. The lysates were centrifuged at 7500g for 10 min-
utes, and the supernatants were collected and stored at
−80◦C until use.
Measurements of cellular ferritin were performed on
cell lysates using a human ferritin enzyme-linked im-
munosorbent assay (ELISA) test kit from BioCheck
(Burlingame, CA, USA). The assay system utilizes 1 rab-
bit antiferritin antibody for solid phase immobilization
and a mouse monoclonal antiferritin antibody in the
antibody-enzyme (horseradish peroxidase) conjugate so-
lution. Protein concentrations were determined with the
Bradford method (BioRad, Hercules, CA, USA).
Assessment of transferrin-chelatable iron
Transferrin-chelatable iron was assayed by iron free
fluorescent-transferrin (fluorescent apo-transferrin; Fl-
aTf), whose fluorescence is stoichiometrically quenched
by iron that binds to the protein. Fluorescent apo-
transferrin was prepared according to the method
of Breuer et al [35]. In brief, 100 lmol/L 5-(4,6-
dichlorotriazinyl) aminofluorescein (from a freshly pre-
pared 10 mmol/L solution in dimethylsulfoxide) was
added to a solution containing 8 mg/mL apo-transferrin
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in 100 mmol/L NaHCO3, pH 8.4. After incubation for
30 minutes at 37◦C in the dark, the coupling reaction
was stopped by 5 mmol/L L-lysine, pH 8.0, and the pro-
tein was dialyzed against HEPES-buffered saline (HBS:
150 mmol/L NaCl, 20 mmol/L HEPES, pH 7.3) and stored
at −20◦C.
To assay for transferrin-chelatable iron, 10 lL of the
sample was placed in quadruplicates in black 96-well
plates with clear, flat bottoms (Greiner, Graz, Austria).
Two of the wells were incubated with 180 lL reagent
A (containing 1 lmol/L Fl-aTf in HBS), the other 2
wells were incubated with 180 lL reagent B (containing
1 lmol/L Fl-aTf, 5 mmol/L EDTA in HBS). After incu-
bation (1 hour in the dark at 25◦C), the fluorescence was
measured in a fluorescence plate reader (Victor II) from
Perkin Elmer (excitation 485 nm, emission 535 nm).
The ratio between the fluorescence of the samples ob-
tained with reagents A (reading A) and B (reading B)
was calculated, and the iron concentration was derived
from a calibration curve with freshly prepared ferrous
ammonium sulfate (FAS) in doubly deionized water.
Measurement of ferrozine-chelatable ferrous iron
Ferrozine can form a colored complex with ferrous iron
(Fe2+) that can be determined photometrically at 540 nm.
Ferric iron (Fe3+) in the preparations is firmly bound and
has to be reduced and mobilized from the preparations
to form the colored Fe2+-ferrozine complex.
The effect of ascorbic acid on the amount of ferrozine-
chelatable iron in the preparations was assayed by mixing
of 150 lL ferrozine reagents (containing 64 mg ferrozine,
64 mg neocuproine, and 7.76 g ammonium acetate dis-
solved in 20 mL doubly deionized water) with 400 lL of
a solution containing 75 lmol/L IVI and 0 to 200 lmol/L
ascorbic acid in PBS. The samples were incubated for
2 hours at 37◦C in the dark, and the amount of ferrozine-
chelatable iron was derived from a calibration curve with
freshly prepared ferrous ammonium sulfate (FAS) in
doubly deionized water.
Measurement of low-molecular-weight iron
Mobilization of low-molecular-weight iron from the
iron preparations by ascorbic acid was assayed in hu-
man serum. Serum from a healthy person was incubated
with 75 lmol/L IVI in combination with various con-
centrations of ascorbic acid at 37◦C for 3 hours in the
dark. Then the samples were centrifuged through a 10 kD
molecular weight cut-off filter (Roth, Graz, Austria), and
the iron content of the filtrate and the original sample
was quantified for iron by AAS. The iron content of the
original sample was set as 100%, and the percentage of
low-molecular-weight iron concentration in the samples
was calculated from the iron concentration in the original
sample and in the filtrate.
Neutral red cytotoxicity assay
The neutral red (NR) cytotoxicity assay procedure is
a cell survival/viability chemosensitivity assay based on
the ability of viable cells to incorporate and bind neu-
tral red, a supravital dye. NR is a weak cationic dye that
readily penetrates cell membranes by nonionic diffusion,
accumulating intracellularly in lysosomes, where it binds
with anionic sites in the lysosomal matrix. Alterations
of the cell surface or the sensitive lysosomal membrane
lead to lysosomal fragility and other changes that grad-
ually become irreversible. Such changes brought about
by the action of xenobiotics result in a decreased uptake
and binding of NR. It is therefore possible to distinguish
between viable, damaged, or dead cells, which is the basis
of this assay [34].
The cells were incubated with DMEM alone (control)
with DMEM containing 75 lmol/L IVI or with DMEM
containing 75 lmol/L IVI and 150 lmol/L ascorbic acid
for 6 hours at 37◦C. After removal of the incubation
medium, the cells were washed with DMEM and incu-
bated with neutral red (50 mg/L in DMEM) for 3 hours
at 37◦C. The cells were washed 3 times with PBS and
incubated with 200 lL of 50% ethanol (v/v), 1% acetic
acid (v/v) in distilled water for 20 minutes at 37◦C, and
absorbance at 540 nm was read in a fluorescence plate
reader (Victor II) from Perkin Elmer.
Statistical analysis
Results are presented as mean ± SEM from 3 inde-
pendent experiments carried out in duplicates. Statistical
analysis was performed with GraphPad Prism software.
Differences were examined for statistical significance us-
ing the paired t test. Significant differences are marked in
the figures with ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001.
Differences with P < 0.05 were assumed to be significant.
RESULTS
Effect of ascorbic acid on iron bioavailability from IVI
Recently, we showed by the fluorescent calcein-assay
that parenteral iron preparations entered the LIP of
HepG2 cells. We showed that the amount of bioavailable
iron varies among different classes of IVI preparations
[33]. The LIP increased lowest with iron dextran, which is
known to be the iron preparation with the highest chem-
ical stability [7]; iron sucrose was intermediate and ferric
gluconate, the weakest iron complex, was most effective
to increase the LIP within a short time.
Here we show that the addition of ascorbic acid in-
creased the amount of bioavailable iron from iron sucrose
significantly (P < 0.015) (Fig. 1). After 4 hours of incuba-
tion with iron sucrose alone the LIP increased 2-fold com-
pared to control, whereas a combined incubation with
iron sucrose and ascorbic acid increased the LIP about
4-fold compared to control. According to the increased
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Fig. 1. Effect of ascorbic acid on iron-bioavailability from the prepa-
rations. HepG2 cells were exposed to IVI (75 lmol/L) [±150 lmol/L
ascorbic acid (AA)] between 0 to 4 hours. After removal of the incu-
bation medium and washing of the cells, they were loaded with calcein-
AM (0.25 lmol/L), washed and incubated with DMEM, containing
20 mmol/L HEPES and anticalcein antibody to quench extracellular
calcein-fluorescence. After registration of the baseline fluorescence, the
amount of intracellular metal bound to calcein (Ca-Fe) was assessed
by addition of 100 lmol/L of the fast permeating chelator SIH, which
removes all iron from calcein. The increase in calcein fluorescence is
proportional to the size of the intracellular labile iron pool. Calcein
fluorescence was measured when the signal reached full fluorescence
and remained stable (after 2 minutes). Data are represented as mean ±
SEM from 3 independent experiments performed in duplicates. Error
bars are not shown when they are smaller than the symbols. ∗P < 0.015
vs. IVI treatment alone.
bioavailability of iron with supplementary ascorbic acid
treatment, we could also find a higher ferritin synthesis
following combined preincubation with iron sucrose and
ascorbic acid (see below).
Interestingly, with iron dextran, the iron complex with
the highest chemical stability, but also with ferric glu-
conate, the weakest iron complex, the observed changes
in iron bioavailability with supplementary ascorbic acid
treatment were not significantly different from those with
IVI alone.
Changes in ferritin synthesis in the presence of ascorbic
acid and IVI
The ferritin content of HepG2 cells exposed to IVI
(75 lmol/L) increased with time. Apparently, the higher
the initial increase in the LIP, the faster the synthesis of
ferritin is turned on, leading to a quicker disappearance
of labile iron. Ferritin synthesis turned on first with fer-
ric gluconate, followed by iron sucrose and iron dextran.
Again, this sequence in increasing ferritin synthesis corre-
sponds to the chemical stability of the IVI preparations
and their ability to increase the LIP. This was already
shown by Sturm et al [33] with IVI alone.
In this study, we could confirm this reported relation-
ship between ferritin synthesis and LIP upon combined
incubation with IVI and ascorbic acid. As expected from
the observed increase of the cellular LIP with supple-
mentary ascorbic acid treatment after exposure to iron
sucrose (Fig. 1), ferritin synthesis significantly increased
following combined preincubation with iron sucrose and
ascorbic acid. Furthermore, the time course of ferritin
synthesis corresponded to the increase in the LIP. As ex-
pected from the effects of ascorbic acid on iron bioavail-
ability for the LIP (Fig. 1), a combined incubation of
ascorbic acid with ferric gluconate and iron dextran did
not influence ferritin content compared to incubation
with IVI alone.
Table 1 data show that HepG2 cells were exposed to
IVI (75 lmol/L) ± ascorbic acid (150 lmol/L) between 2
and 6 hours, washed of surface bound iron, lysed, soni-
cated, and stored at −80◦C until use. The ferritin content
was determined by ELISA as described in the experi-
mental section and correlated to a standard curve. Data
(ng ferritin/mg protein) are presented as mean ± SEM
of 3 independent experiments, performed in duplicates
(data from the measurements without ascorbic acid were
published in Sturm et al [33]).
Effect of ascorbic acid on cytotoxicity
As shown in Figure 1, ascorbic acid could significantly
increase iron bioavailability from iron sucrose. It was
therefore interesting to test if increased iron bioavailabil-
ity from the preparations with ascorbic acid is accompa-
nied by increased cytotoxicity for the cells. Results from
the neutral red cytotoxicity assay revealed that supple-
mentary ascorbic acid treatment did not result in signif-
icantly increased cytotoxicity compared to control cells
and cells treated with IVI alone (Fig. 2). The IVI con-
centrations that were used were in the range that can be
expected in patients treated with IVI. In addition, there
were no signs of cytotoxicity during an incubation period
of 6 hours.
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Table 1. Changes in cellular ferritin content in the presence of IVI and ascorbic acid
Time 2 hours 4 hours 6 hours
Ascorbic acid + − + − + −
Controla 1.16 ± 0.15 1.66 ± 0.10 1.33 ± 0.19 1.41 ± 0.28 1.60 ± 0.25 1.03 ± 0.10
Iron Sucrose 1.74 ± 0.67 1.75 ± 0.03 4.67 ± 0.08 2.55 ± 1.17 10.03 ± 0.42 6.32 ± 1.50
Ferric Gluconate 3.20 ± 0.30 4.56 ± 0.05 9.38 ± 0.43 9.76 ± 1.18 13.71 ± 0.50 14.39 ± 0.65
Iron Dextran 1.60 ± 0.37 1.90 ± 0.06 3,09 ± 0.30 3.31 ± 0.81 3.09 ± 0.30 4.60 ± 1.95
aCellular ferritin content of control cells at time t = 0 h: control (−ascorbic acid): 1.29 ± 0.10 ng ferritin/mg protein, Control (+ ascorbic acid): 1.55 ± 0.27 ng
ferritin/mg protein.
Effect of ascorbic acid on the release
of ferrozine-chelatable iron
In the preparations, ferric iron (Fe3+) is bound to a
high-molecular-weight complex (e.g., dextran, gluconate,
or sucrose). Since ascorbic acid has not only iron-
chelating properties, but is also a strong reductant, it
raised the question whether more ferrous iron (Fe2+)
may be generated during incubation of IVI in combina-
tion with ascorbic acid. The iron chelating and reducing
properties of ascorbic acid could be important, since it
is not known if cells take up IVI as a whole complex or
following release of iron from the complex. Ferrous iron
(Fe2+) could then be taken up from the cells by the di-
valent metal transporter DMT1, which is up-regulated in
IVI-treated HepG2 cells [37].
Ascorbic acid-dependent generation of ferrous iron
(Fe2+) from the preparations was assessed using fer-
rozine, which can form colored complexes with ferrous
iron. Increasing concentrations of ascorbic acid signifi-
cantly enhanced generation of ferrozine-chelatable iron
from the complexes in vitro (Fig. 3). Ascorbic acid highly
increased the amount of ferrozine-chelatable iron from
iron sucrose (up to 2.5-fold), was less effective in the case
of ferric gluconate, and even less effective in the case of
iron dextran. Therefore, the ability for reductive iron re-
lease from the preparations markedly differs from their
chemical stability [7].
Ascorbic acid-dependent mobilization of iron from IVI
to transferrin
Ascorbic acid mobilized iron from IVI in vitro (Fig. 3).
Since transferrin is the physiologic iron donor for ery-
thropoiesis, it was of interest if serum transferrin could
bind iron, which was mobilized by ascorbic acid.
Human serum, which was at first depleted from trans-
ferrin by using a 50 kD cut-off filter, was supplemented
with iron free fluorescent transferrin (fluorescent apo-
transferrin; FL-aTf), whose fluorescence is stoichiometri-
cally quenched through the binding of iron to transferrin
[35]. After addition of IVI (± ascorbic acid), we found
a small but significant (P < 0.05) increase in iron bind-
ing to transferrin with ferric gluconate in the presence
of ascorbic acid after 1 hour of incubation. Ascorbic acid
increased iron mobilization from iron sucrose to transfer-
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tected photometrically with the ferrozine assay described in Methods.
Data are represented as mean ± SEM of 3 independent experiments,
performed in duplicates. Some of the error bars are almost as thin as
the upper line of the bar. ∗P < 0.05 vs. 0 lmol/L AA; ∗∗P < 0.01 vs. 0
lmol/L AA; ∗∗∗P < 0.001 vs. 0 lmol/L AA.
rin approximately 2-fold (P < 0.002) at all time points. In
contrast, ascorbic acid had no effect on iron mobilization
from iron dextran (Fig. 4).
The ability of ascorbic acid to mobilize iron from the
preparations to transferrin is therefore markedly differ-
ent from their chemical stability [7].
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Low-molecular-weight iron in human serum
supplemented with IVI and ascorbic acid
The previous data show that ascorbic acid can mobi-
lize iron from IVI. Theoretically, this could result in the
appearance of potentially redox-active low-molecular-
weight iron in the plasma, leading to the generation of
oxidative stress.
To test this hypothesis, we incubated human serum
with IVI in combination with different concentrations of
ascorbic acid. After 3 hours of incubation, the samples
were analyzed for low-molecular-weight iron by ultrafil-
tration through a 10 kD cut-off filter.
Although we could find an ascorbic acid-dependent
mobilization of iron from IVI in buffer (Fig. 3), no in-
crease in low-molecular-weight iron could be observed
(Fig. 5). When normal human serum was incubated with
75 lmol/L Fe-PP (which represents pure low-molecular-
weight iron and was used as a standard) for 3 hours,
more than 90% of the iron was bound to serum compo-
nents. Less than 10% could be filtered through a 10 kD
cut-off filter, which means that about 10% was low-
molecular-weight iron. Interestingly, the addition of up
to 300 lmol/L ascorbic acid did not change the amount
of low-molecular-weight iron in the serum.
DISCUSSION
The inability to mobilize iron from iron storage sites
in quantities sufficient to match the demands constitutes
the mechanism of functional iron deficiency in ESRD pa-
tients. On treatment with recombinant human erythro-
poietin (rHuEPO), they develop functional or absolute
iron deficiency if they are not adequately supplemented
with iron [2]. Therefore, iron supplementation enhances
the efficacy of rHuEPO therapy. It has been shown that
intravenous iron therapy allows rHuEPO dose reduction
by approximately 40%, and is much more effective than
oral iron treatment [10].
There is a need for an adjuvant therapy to improve
iron supply for hemoglobin synthesis and to increase
rHuEpo response in iron-overloaded dialysis patients.
Adjuvant treatments other than iron supplementation
have been investigated in combination with rHuEPO in
iron-overloaded hemodialysis patients. Gastaldello et al
[38] and Tarng et al [31] found intravenous ascorbic acid
administration to be effective in these cases. Deicher et al
[39] found evidence that vitamin C plasma levels account,
at least partly, for the response to rHuEpo.
Vitamin C deficiency has been reported in HD patients,
owing to inadequate dietary intake, loss through the dia-
lyzer, and uremia-associated metabolic derangement [42,
43]. A daily dose of 100 to 200 mg is recommended in
some reports [42–44], but the prescription of vitamin C in
different dialysis facilities varies between 55 and 1000 mg
daily [42–44].
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Fig. 4. Ascorbic acid-dependent mobilization of iron from IVI to trans-
ferrin. Transferrin-depleted human serum was incubated with 1 lmol/L
iron free fluorescent transferrin (fluorescent apo-transferrin; Fl-apo-
Tf), 75 lmol/L of IVI ± 150 lmol/L ascorbic acid (AA) for 1 to 3 hours
at 37◦C in the dark. The fluorescence was measured at Ex 485 nm/Em
535 nm in a fluorescence plate reader. The ratio between the incuba-
tion with and without 5 mmol/L EDTA was calculated and correlated
to a standard curve. The IVI preparations used were (A) iron sucrose,
(B) ferric gluconate, (C) iron dextran. Data are represented as mean ±
SEM of 3 independent experiments, performed in duplicates. No error
bars are shown when they are smaller than the symbols. Significant dif-
ferences were tested vs. the same IVI preparation without AA at the
same time point. ∗P < 0.05; ∗∗P < 0.01.
On the other hand, concerns against vitamin C treat-
ment are raised from the potential risk of uremia-related
oxalosis [45, 46]. Moreover, due to the pro-oxidant ef-
fect of ascorbate and potentially harmful interactions
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Fig. 5. Low-molecular-weight iron in human
serum supplemented with IVI and ascorbic
acid. Human serum was incubated with 75
lmol/L IVI in combination with ascorbic acid
(0–300 lmol/L) at 37◦C in the dark. Af-
ter 3 hours the samples were analyzed for
low-molecular-weight iron by ultrafiltration
through a 10 kD cutoff filter. Iron in the sam-
ples and in the filtrate was quantified by AAS.
Data are represented as mean ± SEM of 3
independent experiments, performed in du-
plicates. Some error bars are smaller than the
symbols. ∗∗P < 0.01 vs. control (no IVI and
AA).
between ascorbate and iron, which may cause oxida-
tive damage to biological macromolecules, concerns have
been raised about supplemental vitamin C intake. Espe-
cially in individuals with high iron status or clinical iron
overload [22, 47], but also in dialysis patients with high
serum ferritin, ascorbate administration can yield pro-
oxidant effects [23]. The notion that ascorbate acts as
a pro-oxidant in the presence of transition metal ions
is based on the ability of ascorbate to enhance metal
ion-dependent hydroxyl and alkoxyl radical formation in
vitro by Fenton chemistry. However, due to the presence
of various metal binding plasma proteins such as transfer-
rin, ferritin, and ceruloplasmin, the availability of “free”
redox-active metal ions in plasma and other biological
fluids is very low [48].
In this study, we investigated the effects of ascorbic acid
on 3 IVI preparations. It is the first report about direct
effects of ascorbic acid on intravenous iron preparations.
Recently, we showed in a cell culture model with
HepG2 cells that all IVI preparations could increase the
intracellular LIP, where ferric gluconate was most ef-
fective followed by iron sucrose and iron dextran [33].
This order corresponds to the known chemical stability
of these intravenous iron preparations, which is highest
with iron dextran, intermediate with iron sucrose, and
lowest with ferric gluconate [7].
The most important findings of this study are that the
effects seen with ascorbic acid on the size of chelatable
and bioavailable iron from the preparations show a differ-
ent order. Whereas ascorbic acid could further increase
the amount of bioavailable iron from iron sucrose in
HepG2 cells, which was mirrored by enhanced ferritin
synthesis, ascorbic acid had no additional effects on the
LIP with ferric gluconate and iron dextran. Ascorbic acid
mobilized iron from all IVI preparations in vitro, but
could increase the amount of bioavailable iron for the
tissue culture model from iron sucrose only. Moreover,
toxicity of IVI in the presence of ascorbic acid was not
increased in HepG2 cells.
Transferrin is the physiologic iron donor for erythro-
poiesis. Ascorbic acid-dependent iron mobilization from
parenteral iron complexes to transferrin would therefore
increase iron availability for erythropoiesis. Ferric glu-
conate, which is the most efficient donor of iron to serum
transferrin, showed a small but significant increase in iron
binding to transferrin upon incubation with ascorbic acid
for 1 hour. Iron sucrose, which is a less efficient donor,
showed an increase in iron binding to transferrin at all
time points in the presence of ascorbic acid. In contrast,
ascorbic acid had no additional effect on iron mobiliza-
tion from iron dextran. Moreover, there was no increase
of potentially harmful low-molecular-weight iron in the
serum after combined incubation of iron sucrose with
ascorbic acid. These results indicate that iron mobilized
from IVI by ascorbic acid would mainly be scavenged by
serum transferrin and other serum components in the cir-
culation and should, therefore, be considered as nontoxic.
Taken together, our results show that bioavailability of
iron from iron sucrose was improved by ascorbic acid,
which resulted in an increase in the LIP, enhanced fer-
ritin synthesis, and increased transfer of iron from iron
sucrose to transferrin. In general, ferric gluconate and
iron dextran did not show significant effects upon the ad-
dition of ascorbic acid. A possible explanation for the
differences seen with ascorbic acid on additional iron
availability from the preparations could be related to its
iron chelating and iron reducing properties. One could
hypothesize that ferric gluconate, the weakest iron com-
plex, does not benefit from an additional iron mobilizing
agent, like ascorbic acid, to make its iron more bioavail-
able. With this iron preparation alone the increase in the
LIP, reflecting iron bioavailability, has already reached a
maximal value, and no further increase seems possible.
This was already shown by Sturm et al [33], where ef-
fects of ferric gluconate on the LIP were compared with
effects seen with low-molecular-weight iron (ferric py-
rophosphate). Ferric gluconate showed roughly the same
quantitative effects on the LIP as low-molecular-weight
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iron. Iron bioavailability from iron sucrose alone did not
reach this maximal LIP value, but in the presence of ascor-
bic acid iron was mobilized and increased the size of the
LIP. Ascorbic acid is also a strong reductant that gener-
ates ferrous iron (Fe2+) by reductive iron release from
iron sucrose in vitro. Ferrous iron could then, in prin-
ciple, enter the cells via the divalent metal transporter
DMT1, a Fe2+ ion transporter at the plasmamembrane
and increase the intracellular LIP. Bioavailability from
iron dextran, which has also the longest half life time in
plasma after intravenous administration, was lowest in
HepG2 cells, which was reflected by a very slow increase
in the LIP. Vitamin C was largely ineffective to mobilize
iron from iron dextran in vitro as well as in HepG2 cells.
This could be related to the inability of ascorbic acid to get
access to the polynuclear iron core, resulting in a much
lower reductive iron release (ferrozine-chelatable Fe2+
in Fig. 3) compared to other IVI preparations.
The exact cellular metabolism of the iron preparations
is not known. However, there is growing direct or indirect
evidence that tissues other than the reticuloendothelial
system are also able to incorporate IVI [37, 49, 50]. The
iron preparations are high-molecular-weight complexes,
and cells, including macrophages, take them up by a yet
unknown mechanism, possibly by vacuolar endocytosis.
It is therefore quite possible that some IVI ends up as
whole complex inside the cells.
Ascorbic acid treatment was used in several studies to
overcome functional iron deficiency in rhuEpo hypore-
sponsive HD patients. In view of our results, it is therefore
also tempting to predict a better response to ascorbic acid
treatment in patients previously treated with iron sucrose.
So far, IVI therapy is considered to be safe but efficacy
still needs optimization.
CONCLUSION
We conclude that corrected ascorbic acid levels in HD
patients could increase the amount of bioavailable iron
from iron sucrose, but not from other classes of IVI. Vi-
tamin C administration could therefore result in the need
of lower iron sucrose dosages to correct anemia. Further
studies are necessary to determine safety and efficacy of
different classes of IVI in correlation to patients’ plasma
ascorbic acid levels.
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